康泰生物
(300601)
| 流通市值：123.93亿 | | | 总市值：156.26亿 |
| 流通股本：8.86亿 | | | 总股本：11.17亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 645,202,778.57 | 2,651,715,620.99 | 2,018,201,664.48 | 1,202,065,325.16 |
| 营业收入 | 645,202,778.57 | 2,651,715,620.99 | 2,018,201,664.48 | 1,202,065,325.16 |
| 二、营业总成本 | 594,453,971.64 | 2,301,437,136.57 | 1,597,573,808.72 | 1,012,244,950.53 |
| 营业成本 | 171,263,111.04 | 477,417,300.48 | 334,020,470.6 | 195,012,638.03 |
| 税金及附加 | 4,074,049.56 | 30,554,872.79 | 17,464,905.54 | 13,659,470.12 |
| 销售费用 | 208,030,761.82 | 887,247,447.88 | 671,404,158.08 | 396,897,429.33 |
| 管理费用 | 83,424,298.47 | 372,139,697.78 | 244,620,221.51 | 174,934,071.28 |
| 研发费用 | 120,628,293.1 | 508,122,984.22 | 311,770,025.07 | 220,188,982.26 |
| 财务费用 | 7,033,457.65 | 25,954,833.42 | 18,294,027.92 | 11,552,359.51 |
| 其中:利息费用 | 29,490,038.16 | 124,120,956.32 | 93,082,420.87 | 63,519,485.4 |
| 其中:利息收入 | 22,823,545.17 | 98,385,328.38 | 75,170,822.53 | 51,972,106.35 |
| 加:公允价值变动收益 | - | 1,380,868.09 | 934,768.09 | 854,668.09 |
| 加:投资收益 | - | 465,020.57 | 481,740.54 | 481,740.54 |
| 资产处置收益 | -185,216.7 | -8,415,471.25 | -13,000.28 | 95,364.87 |
| 资产减值损失(新) | -22,308,160.78 | -231,519,516.32 | -104,644,795.88 | -68,292,407.4 |
| 信用减值损失(新) | -7,979,260.95 | -29,476,786.93 | -37,534,638.91 | -36,067,174.88 |
| 其他收益 | 7,861,405.83 | 98,511,776.62 | 61,279,404.53 | 55,801,083.87 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 28,137,574.33 | 181,224,375.2 | 341,131,333.85 | 142,693,649.72 |
| 加:营业外收入 | 719,855.74 | 4,218,032.16 | 3,793,596.9 | 3,251,869.32 |
| 减:营业外支出 | 1,888,252.63 | 35,505,427.57 | 10,463,587.4 | 9,255,082.19 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 26,969,177.44 | 149,936,979.79 | 334,461,343.35 | 136,690,436.85 |
| 减:所得税费用 | 4,584,067.37 | -51,616,743.01 | -16,614,430.67 | -28,661,575.79 |
| 六、净利润 | 22,385,110.07 | 201,553,722.8 | 351,075,774.02 | 165,352,012.64 |
| 持续经营净利润 | 22,385,110.07 | 201,553,722.8 | 351,075,774.02 | 165,352,012.64 |
| 归属于母公司股东的净利润 | 22,434,088.56 | 201,652,296.41 | 351,095,608.08 | 165,336,345.29 |
| 少数股东损益 | -48,978.49 | -98,573.61 | -19,834.06 | 15,667.35 |
| (一)基本每股收益 | 0.02 | 0.18 | 0.31 | 0.15 |
| (二)稀释每股收益 | 0.02 | 0.18 | 0.31 | 0.15 |
| 八、其他综合收益 | -56,881.31 | -90,939.67 | -137,744.56 | -54,412.97 |
| 归属于母公司股东的其他综合收益 | -56,881.31 | -90,939.67 | -137,744.56 | -54,412.97 |
| 九、综合收益总额 | 22,328,228.76 | 201,462,783.13 | 350,938,029.46 | 165,297,599.67 |
| 归属于母公司股东的综合收益总额 | 22,377,207.25 | 201,561,356.74 | 350,957,863.52 | 165,281,932.32 |
| 归属于少数股东的综合收益总额 | -48,978.49 | -98,573.61 | -19,834.06 | 15,667.35 |
| 公告日期 | 2025-04-21 | 2025-04-21 | 2024-10-26 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |